Cresset's FieldStere generates non-obvious drug candidates

Cresset BioMolecular Discovery (Cresset) has launched FieldStere, a software product that enables medicinal chemists to enrich their shortlist of drug candidates with structurally diverse compounds that share the same desired biological activity (bioisosteres). It allows the fine-tuning of the resulting bioisosteres to enhance potency and specificity while removing undesirable ADME and physical properties.

The new FieldStere product builds on Cresset's Field technology, which describes chemical structures in terms of the surface properties of the whole molecule. These determine, more accurately than existing tools, how a compound will interact with other molecules, the company says.

"Our clients recognised the potential of our Field technology in a range of areas such as lead optimisation, candidate switching, compound evaluation and investigation of new patent opportunities around existing therapeutics," said Bea Leigh, ceo of Cresset. "In pre-launch testing, users reported that the product consistently identified both known bioisosteres and non-obvious, structurally diverse compounds."

These non-obvious compounds increase the medicinal chemistry repertoire and can represent novel product opportunities unprotected by existing patents, the company says. As a result, FieldStere has application in the development of patent strategy for the protection of new molecular entities, identifying follow-on compounds as marketed products come off patent and lead optimisation of new drugs.

FieldStere will be sold through Cresset's sales operations and offered as part of a leveraged service to companies needing to access specialist chemistry services.

Cresset BioMolecular Discovery

T +44 1707 356120